stoxline Quote Chart Rank Option Currency Glossary
  
Eterna Therapeutics Inc. (ERNA)
0.3072  0.019 (6.74%)    02-14 16:00
Open: 0.3109
High: 0.3231
Volume: 818,895
  
Pre. Close: 0.2878
Low: 0.2839
Market Cap: 16(M)
Technical analysis
2025-02-14 4:47:48 PM
Short term     
Mid term     
Targets 6-month :  0.8 1-year :  1.12
Resists First :  0.68 Second :  0.95
Pivot price 0.34
Supports First :  0.25 Second :  0.2
MAs MA(5) :  0.28 MA(20) :  0.39
MA(100) :  0.63 MA(250) :  1.4
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  13.8 D(3) :  7.4
RSI RSI(14): 42.6
52-week High :  2.63 Low :  0.21
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ERNA ] has closed above bottom band by 33.2%. Bollinger Bands are 48.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.32 - 0.33 0.33 - 0.33
Low: 0.28 - 0.28 0.28 - 0.28
Close: 0.3 - 0.31 0.31 - 0.31
Company Description

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Headline News

Wed, 15 Jan 2025
ERNA-101 extends survival in mice with ovarian cancer - BioWorld Online

Tue, 14 Jan 2025
Eterna's ERNA-101 Shows Breakthrough Results in Ovarian Cancer Treatment Study - StockTitan

Tue, 14 Jan 2025
Eterna Therapeutics Reports Positive Preclinical Results For ERNA-101 In Ovarian Cancer - Nasdaq

Mon, 13 Jan 2025
Eterna Therapeutics faces Nasdaq delisting over market value - Investing.com

Fri, 10 Jan 2025
Eterna Therapeutics Faces Nasdaq Compliance and Board Changes - TipRanks

Mon, 06 Jan 2025
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 51 (M)
Held by Insiders 3.28e+006 (%)
Held by Institutions 336.3 (%)
Shares Short 54 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.186e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -10 %
Return on Assets (ttm) 491.4 %
Return on Equity (ttm) -29.5 %
Qtrly Rev. Growth 162000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -23166
Qtrly Earnings Growth -8.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 5.82
Stock Dividends
Dividend 0
Forward Dividend 44460
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android